CLOs on the Move

Micell Technologies

www.micell.com

 
Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.micell.com
  • 7516 Precision Dr
    Raleigh, NC USA 27617
  • Phone: 919.313.2102

Executives

Name Title Contact Details

Similar Companies

ESSA Pharma

As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.

SpIntellx

See More. Know More. Power Precision Pathology.

ADC Therapeutics

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dova Pharmaceuticals

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...